Published in Respiratory Therapeutics Week, June 12th, 2006
"Budesonide/formoterol 160/4.5 mc g, two inhalations bd, is an effective and well-tolerated maintenance therapy for patients not controlled on inhaled corticosteroids alone. The authors assessed the efficacy and safety of a higher dose of budesonide/formoterol in patients with persistent symptomatic asthma. This was a 24-week, double-blind, double-dummy randomized study," scientists in Australia report.
C. Jenkins and colleagues, Woolcock Institute of Medical Research, explained, "Budesonide/formoterol 320/9...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.